Log in

NASDAQ:ARVNArvinas Stock Price, Forecast & News

$31.50
-0.95 (-2.93 %)
(As of 07/31/2020 04:00 PM ET)
Add
Compare
Today's Range
$30.52
Now: $31.50
$32.40
50-Day Range
$29.88
MA: $33.17
$36.34
52-Week Range
$15.19
Now: $31.50
$61.57
Volume339,440 shs
Average Volume295,189 shs
Market Capitalization$1.23 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.71
Arvinas, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead products include ARV-110, proteolysis targeting chimeras (PROTAC) that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC targeting the estrogen receptor protein for the treatment of women with metastatic ER positive/HER2 negative breast cancer. The company is also developing other PROTACs for degrading AR and other clinically relevant AR point mutations; and various other products for the treatment of neurodegenerative diseases, including tauopathies. Arvinas, Inc. was founded in 2015 and is based in New Haven, Connecticut.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.37 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ARVN
CUSIPN/A
CIKN/A
Phone203-535-1456

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$42.98 million
Book Value$6.72 per share

Profitability

Net Income$-70,290,000.00
Net Margins-171.74%

Miscellaneous

Employees83
Market Cap$1.23 billion
Next Earnings Date8/3/2020 (Estimated)
OptionableNot Optionable
$31.50
-0.95 (-2.93 %)
(As of 07/31/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ARVN News and Ratings via Email

Sign-up to receive the latest news and ratings for ARVN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Arvinas (NASDAQ:ARVN) Frequently Asked Questions

How has Arvinas' stock been impacted by COVID-19 (Coronavirus)?

Arvinas' stock was trading at $44.06 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ARVN stock has decreased by 28.5% and is now trading at $31.50.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Arvinas?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arvinas in the last year. There are currently 1 hold rating and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Arvinas
.

When is Arvinas' next earnings date?

Arvinas is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020.
View our earnings forecast for Arvinas
.

How were Arvinas' earnings last quarter?

Arvinas Inc (NASDAQ:ARVN) posted its quarterly earnings data on Tuesday, April, 28th. The company reported ($0.56) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.57) by $0.01. The company earned $6.24 million during the quarter, compared to analyst estimates of $5.18 million. Arvinas had a negative return on equity of 30.74% and a negative net margin of 171.74%.
View Arvinas' earnings history
.

What price target have analysts set for ARVN?

11 brokerages have issued 1-year target prices for Arvinas' stock. Their forecasts range from $38.00 to $75.00. On average, they anticipate Arvinas' stock price to reach $57.10 in the next year. This suggests a possible upside of 81.3% from the stock's current price.
View analysts' price targets for Arvinas
.

Has Arvinas been receiving favorable news coverage?

News coverage about ARVN stock has trended negative on Monday, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Arvinas earned a media sentiment score of -2.9 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the next few days.
View the latest news about Arvinas
.

Are investors shorting Arvinas?

Arvinas saw a increase in short interest in June. As of June 30th, there was short interest totaling 3,300,000 shares, an increase of 13.8% from the June 15th total of 2,900,000 shares. Based on an average trading volume of 608,400 shares, the short-interest ratio is currently 5.4 days. Approximately 12.9% of the company's shares are sold short.
View Arvinas' Current Options Chain
.

Who are some of Arvinas' key competitors?

What other stocks do shareholders of Arvinas own?

Who are Arvinas' key executives?

Arvinas' management team includes the following people:
  • Dr. John G. Houston Ph.D., CEO, Pres & Director (Age 59)
  • Mr. Sean A. Cassidy, CFO & Treasurer (Age 49)
  • Dr. Ian Taylor, Chief Scientific Officer (Age 56)
  • Dr. Craig M. Crews, Founder, Chief Scientific Advisor & Member of Scientific Advisory Board
  • Dr. Andrew Crew, Chief Technology Officer (Age 54)

When did Arvinas IPO?

(ARVN) raised $100 million in an initial public offering on Thursday, September 27th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Goldman Sachs, Citigroup and Piper Jaffray acted as the underwriters for the IPO.

What is Arvinas' stock symbol?

Arvinas trades on the NASDAQ under the ticker symbol "ARVN."

Who are Arvinas' major shareholders?

Arvinas' stock is owned by a variety of retail and institutional investors. Top institutional investors include Candriam Luxembourg S.C.A. (0.93%), First Trust Advisors LP (0.11%), UBS Group AG (0.06%), Strs Ohio (0.05%), SG Americas Securities LLC (0.01%) and Zurcher Kantonalbank Zurich Cantonalbank (0.01%). Company insiders that own Arvinas stock include Bradley Albert Margus, Briggs Morrison, Ian Taylor, James E Flynn, John G Houston, Liam Ratcliffe, Sean A Cassidy, Timothy M Shannon and Ventures Iii LP 5Am.
View institutional ownership trends for Arvinas
.

Which institutional investors are buying Arvinas stock?

ARVN stock was bought by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., First Trust Advisors LP, UBS Group AG, Strs Ohio, Endurance Wealth Management Inc., Zurcher Kantonalbank Zurich Cantonalbank , and SG Americas Securities LLC. Company insiders that have bought Arvinas stock in the last two years include Bradley Albert Margus, Briggs Morrison, Ian Taylor, James E Flynn, Liam Ratcliffe, Sean A Cassidy, and Timothy M Shannon.
View insider buying and selling activity for Arvinas
.

How do I buy shares of Arvinas?

Shares of ARVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Arvinas' stock price today?

One share of ARVN stock can currently be purchased for approximately $31.50.

How big of a company is Arvinas?

Arvinas has a market capitalization of $1.23 billion and generates $42.98 million in revenue each year. The company earns $-70,290,000.00 in net income (profit) each year or ($2.13) on an earnings per share basis. Arvinas employs 83 workers across the globe.

What is Arvinas' official website?

The official website for Arvinas is www.arvinas.com.

How can I contact Arvinas?

Arvinas' mailing address is 5 SCIENCE PARK 395 WINCHESTER AVE, NEW HAVEN CT, 06511. The company can be reached via phone at 203-535-1456 or via email at [email protected]

This page was last updated on 8/3/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.